Lead Sponsor

Novo Nordisk A/S

Age

18 - No limit years

Sex

MALE

Healthy Volunteers

No

•Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
•Male subjects with the diagnosis of severe haemophilia A (FVIII\<1%) from age 18 years
•Documented history of at least 150 exposure days to any other FVIII products (prevention or treatment of bleeds)
•Immunocompetent (HIV (Human Immunodeficiency Virus) positive subjects should have CD4+ (Cluster of differentiation 4; a glycoprotein expressed on the surface) lymphocyte count \>200/microL)

•Detectable inhibitors to FVIII (above or equal to 0.6 Bethesda Units (BU))
•History of FVIII inhibitors
•Severe current hepatic dysfunction or severe hepatic disease during the last 12 months
•Known or suspected allergy to trial product (FVIII) or related products
•Subjects receiving immune modulating medication or immune tolerance induction (ITI) regimens
•Body mass index (BMI) above 30 kg/m\^2

Related studies

NCT06716814 · Haemophilia A (Moderate or Severe)

NCT06352216 · Haemophilia A, Synovitis, and more

NCT06831734 · Haemophilia A, Haemophilia B

NCT06285071 · Haemophilia A, Haemophilia B

NCT06752850 · Haemophilia A (Moderate or Severe), Hemophilia, Classic, and more

Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A